Sun Pharmaceutical Industries has received a major legal boost in its U.S. operations after the U.S. Court of Appeals for the Federal Circuit ruled in its favor and vacated the preliminary injunction that had previously delayed the launch of LEQSELVI™ (deuruxolitinib).
The court decision, made on April 9, 2025, effectively removes all legal barriers that had restricted the company from launching the product in the United States. While the litigation with Incyte Corporation continues, the preliminary injunction is no longer in effect, giving Sun Pharma the freedom to proceed with its market entry strategy for LEQSELVI™.
In an official statement, Sun Pharma confirmed that it will announce launch plans for LEQSELVI™ in due course.
The now-vacated injunction was originally granted by the U.S. District Court for the District of New Jersey and had put the brakes on Sun Pharma’s launch timeline. With the latest ruling, the company can move forward without any court-mandated restrictions.
This development follows Sun Pharma’s earlier intimation to exchanges dated November 2, 2024.
